Danuglipron is an orally active, small-molecule, non-peptide GLP-1 receptor agonist designed for the treatment of metabolic diseases, including Type 2 diabetes and obesity. It is marketed as a final therapeutic compound rather than a reactant or precursor. It is grouped under the following drug class(es): GLP‑1 Receptor Agonists. The directory classifies it as a clinical API with a synthetic source/manufacturing origin. Other names for this substance include Danuglipronum. Its PubChem CID is 134611040.
Danuglipron
| CAS No | 2230198-02-2 |
|---|---|
| Molecular Formula | C31H30FN5O4 |
| Molecular Weight | 555.6 g/mol |
| Synonyms | 2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Danuglipron is an orally active, small-molecule, non-peptide GLP-1 receptor agonist designed for the treatment of metabolic diseases, including Type 2 diabetes and obesity.
The listed CAS number is 2230198-02-2.
The listed molecular formula is C31H30FN5O4.
The listed molecular weight is 555.6 g/mol.
2-[[4-[6-[(4-cyano-2-fluorophenyl)methoxy]-2-pyridinyl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid.
The source lists Danuglipronum.